Sells KIMMTRAK, a therapy for people with uveal melanoma, and develops immune-targeting medicines for cancer, infectious diseases and autoimmune diseases.
10-K for FY2025, filed Feb 25, 2026In 2022, we received approval for our lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma ("mUM") from…View ↗
Unlike antibody targeted immunotherapies that have a relatively small target pool, our approach relies on the power of TCRs, which are…View ↗
We are currently leveraging our platform within three therapeutic areas: cancer, infectious diseases, and autoimmune diseases. Our oncology…View ↗
Distributors are invoiced for KIMMTRAK; sales are counted when it is delivered or when distributors take it from consignment inventory. Historical collaboration agreements brought upfront and milestone payments for technology rights, with related research work carried out over time.
10-K for FY2025, filed Feb 25, 2026Revenue from sale of therapies, net relates to the sale of KIMMTRAK following marketing approval and the sale of tebentafusp under a…View ↗
The Company’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list…View ↗
Under its historical collaboration agreements, the Company granted rights to technology with respect to the development of specified…View ↗
Revenue is recognized using an estimate of percentage completion which takes into consideration the estimated timelines required to satisfy…View ↗
Under the Genentech agreement signed in November 2018, the Company received aggregate non-refundable payments totaling $100 million…View ↗
$400M
10-K for FY2025, filed Feb 25, 2026
$400M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenue from sale of therapies, net
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
100%
FY2022: 81%
|
Revenue from sale of therapies, net, FY2025
$400M Sources
|
Sold outright |
|
Collaboration revenue
|
0.0%
FY2022: 19%
|
Collaboration revenue, FY2025
$0 Sources
|
Distributors are the main customers in the United States and Europe; in some countries, hospitals and healthcare providers buy through agents. Medison and Er-Kim distribute KIMMTRAK in certain markets outside the United States.
10-K for FY2025, filed Feb 25, 2026The Company’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list…View ↗
In certain countries, the Company’s customers are hospitals and healthcare providers, where KIMMTRAK is sold through an agent acting on the…View ↗
Medison is the exclusive distribution partner for KIMMTRAK in Canada, Australia, New Zealand, Israel, Central and Eastern Europe, South and…View ↗
10-K for FY2025, filed Feb 25, 2026
The Company recognized revenues from four customers accounting for 23%, 23%, 17% and 18% of the Company’s revenue from sale of therapies…View ↗
No. It lost $35.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
−$14.2MView ↗
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
Added regional distributor
The company added Er-Kim alongside Medison to distribute and commercialize KIMMTRAK in Turkey, the Middle East, North Africa, the Caucasus and the Commonwealth of Independent States.
20-F for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 25, 2026KIMMTRAK is manufactured at facilities located in Denmark and Germany. We are supporting the appropriate use of KIMMTRAK in the United…View ↗
Medison is the exclusive distribution partner for KIMMTRAK in Canada, Australia, New Zealand, Israel, Central and Eastern Europe, South and…View ↗
Competes with Adaptimmune Therapeutics, Immatics Biotechnologies, Adaptive Biotechnologies, pure MHC, BioNTech, Genentech, Enara Bio, Boehringer Ingelheim International, Anocca, T-Knife, 3T Biosciences, Regeneron Pharmaceuticals, Takara Bio, AstraZeneca, Lion TCR, TCRCure Biopharma, Corregene Biotechnology, TScan Therapeutics, Molecular Partners, and Crossbow Therapeutics
10-K for FY2025, filed Feb 25, 2026We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of TCR-based…View ↗
Loading...